Caprock Group LLC Invests $5 Million in IDEXX Laboratories, Inc. $IDXX

Caprock Group LLC bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 7,721 shares of the company’s stock, valued at approximately $4,996,000.

Other large investors have also recently added to or reduced their stakes in the company. J.Safra Asset Management Corp acquired a new stake in IDEXX Laboratories during the third quarter valued at approximately $31,000. Armstrong Advisory Group Inc. raised its position in shares of IDEXX Laboratories by 55.9% during the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after purchasing an additional 19 shares during the period. Salomon & Ludwin LLC bought a new stake in shares of IDEXX Laboratories in the third quarter valued at about $35,000. Greykasell Wealth Strategies Inc. acquired a new position in IDEXX Laboratories during the third quarter worth $35,000. Finally, WealthCollab LLC bought a new position in IDEXX Laboratories in the second quarter valued at approximately $30,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. BTIG Research lowered their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Leerink Partners set a $785.00 price objective on IDEXX Laboratories in a research note on Monday, November 3rd. JPMorgan Chase & Co. upped their target price on IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Jefferies Financial Group restated a “buy” rating and issued a $830.00 price target on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. Finally, Piper Sandler dropped their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday. Seven investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus target price of $783.33.

IDEXX Laboratories Stock Up 0.3%

Shares of IDEXX Laboratories stock opened at $648.73 on Thursday. The stock’s 50-day moving average is $688.69 and its 200 day moving average is $666.93. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98. The firm has a market cap of $51.80 billion, a price-to-earnings ratio of 49.64, a PEG ratio of 3.93 and a beta of 1.67. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, February 2nd. The company reported $3.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.93 by $0.15. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company’s revenue was up 14.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insider Activity

In related news, EVP George Fennell sold 11,345 shares of the stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the transaction, the executive vice president directly owned 9,823 shares of the company’s stock, valued at $6,352,730.56. This represents a 53.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.98% of the stock is owned by insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.